

## Product datasheet for TL317164V

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### PAM16 Human shRNA Lentiviral Particle (Locus ID 51025)

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** PAM16 Human shRNA Lentiviral Particle (Locus ID 51025)

**Locus ID:** 51025

Synonyms: CGI-136; MAGMAS; SMDMDM; TIM16; TIMM16

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** PAM16 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 016069, NM 016069.1, NM 016069.2, NM 016069.3, NM 016069.4, NM 016069.6,

NM 016069.7, NM 016069.8, BC005024, BC005024.1

UniProt ID: Q9Y3D7

Summary: This gene encodes a mitochondrial protein involved in granulocyte-macrophage colony-

stimulating factor (GM-CSF) signaling. This protein also plays a role in the import of nuclear-encoded mitochondrial proteins into the mitochondrial matrix and may be important in reactive oxygen species (ROS) homeostasis. Mutations in this gene cause Megarbane-Dagher-Melike type spondylometaphyseal dysplasia, an early lethal skeletal dysplasia characterized by short stature, developmental delay and other skeletal abnormalities. [provided by RefSeq,

May 2017]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



#### PAM16 Human shRNA Lentiviral Particle (Locus ID 51025) - TL317164V

# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).